Skip to content
TrialScanner

NCT03051256

Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD

Phase 2CompletedRLMDLead

Registry record

Lead sponsor
Relmada Therapeutics, Inc.
Conditions
Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant
Primary completion
Jul 30, 2019Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03051256 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03051256: Safety, Tolerability, PK... | TrialScanner